Earnings ·
Ginkgo Bioworks reports Q3 revenue of $28M and GAAP net loss of ($41)M
DNAGinkgo Bioworks Holdings, Inc.
Ginkgo Bioworks Holdings reported third-quarter 2026 revenue of $28 million, a 6% decrease from the prior year period but an increase from $20 million in Q2. The company posted a GAAP net loss from continuing operations of ($41) million, improved from ($73) million a year ago, and reported Adjusted EBITDA of ($22) million versus ($53) million previously. Cash burn was $27 million for the quarter, with a cash balance of $285 million at period end. The company reaffirmed its full-year 2026 expected total cash burn guidance of ($150) to ($125) million and highlighted new business wins including an autonomous lab sale to Novo and government contracts with ARPA-H and the NSF. Ginkgo Bioworks builds tools that make biology easier to engineer, offering autonomous laboratories and cloud-based contract research services.